Purpose Of Review: Examine and discuss indications, technique, and outcomes for robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer.
Recent Findings: Open RPLND has been the longstanding standard of care for both primary and post chemotherapy RPLND. Recently, robotic RPLND has been an attractive option with the intent of reducing the morbidity associated with open surgery while providing identical oncologic efficacy. Naysayers of robotic RPLND suggest it is often inappropriately used as a staging procedure and consequently can compromise oncologic efficacy.
Summary: Robotic RPLND is being evaluated as a therapeutic equivalent to open RPLND. On the basis of limited published data with modest follow-up from experienced centers, robotic RPLND appears to provide effective staging and therapeutic data mirroring that of open surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOU.0000000000000530 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour.
BJU Int
December 2024
Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
Objectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications.
Materials And Methods: Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease-free survival (DFS).
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study.
Eur Urol Focus
November 2024
Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Background And Objective: The feasibility and safety of a robotic approach for postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in testicular cancer have been demonstrated, but data on long-term oncological outcomes of this procedure are limited. Our aim was to evaluate oncological outcomes following robotic PC-RPLND in this setting.
Methods: This retrospective cohort study included consecutive patients with testicular cancer treated with robotic PC-RPLND at 11 academic centers worldwide between 2011 and 2023.
Lymph node density as a prognostic marker of relapse in patients who underwent primary retroperitoneal lymph node dissection.
Urol Oncol
December 2024
Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Article Synopsis
- The study investigates the effectiveness of primary retroperitoneal lymph node dissection (pRPLND) as a treatment for testicular germ cell tumors, focusing on lymph node density (LND) as a potential predictor for relapse.
- A total of 178 patients were reviewed, with 77% showing nodal metastasis, but the study found no significant link between LND and relapse-free survival, despite identifying an optimal LND threshold of 26.75%.
- The conclusion states that LND is not a reliable prognostic marker for relapse after pRPLND in testicular germ cell tumors, highlighting the unique characteristics of these tumors.
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience.
Eur Urol Open Sci
July 2024
The Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway.
Background And Objective: There is an unmet need to avoid long-term morbidity associated with standard cytotoxic treatment for low-volume metastatic seminoma. Our aim was to assess the oncological efficacy and surgical safety of retroperitoneal lymph node dissection (RPLND) as treatment in a population-based cohort of metastatic seminoma patients with limited retroperitoneal lymphadenopathy.
Methods: Sixty-two seminoma patients in Norway and Sweden were included in the cohort from 2019 to 2022.
Unilateral Post-Chemotherapy Robot-Assisted Retroperitoneal Lymph Node Dissection for Stage II Non-Seminomatous Germ Cell Tumors: Sexual and Reproductive Outcomes.
Cancers (Basel)
June 2024
Uro-Gynecological Department, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131 Naples, Italy.
We aimed to report sexual and reproductive outcomes following post-chemotherapy robot-assisted retroperitoneal unilateral lymph node dissection (PC-rRPLND) for non-seminomatous germ cell tumors (NSGCTs) at a high-volume cancer center. We collected records regarding sexual and reproductive outcomes of patients undergoing unilateral PC-rRPLND for stage II NSGCTs from January 2018 to November 2021. Preoperative and postoperative (at 12 months) ejaculatory function as well as erectile function, based on the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score (EHS), were assessed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!